June 28, 2026
4 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
VIDEO: Tucatinib extends PFS with no new safety signals in HER2-positive breast cancer
CHICAGO — In this video, Erika P. Hamilton, MD, discusses results from the HER2CLIMB-05 trial of tucatinib in combination with trastuzumab and pertuzumab as first-line maintenance therapy in HER2-positive metastatic breast cancer.The study, which compared tucatinib (Tukysa; Pfizer, Seagen) vs. placebo in combination with trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta,
348 words~2 min read
